AU2007310416A1 - Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of autoimmune diseases - Google Patents
Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of autoimmune diseases Download PDFInfo
- Publication number
- AU2007310416A1 AU2007310416A1 AU2007310416A AU2007310416A AU2007310416A1 AU 2007310416 A1 AU2007310416 A1 AU 2007310416A1 AU 2007310416 A AU2007310416 A AU 2007310416A AU 2007310416 A AU2007310416 A AU 2007310416A AU 2007310416 A1 AU2007310416 A1 AU 2007310416A1
- Authority
- AU
- Australia
- Prior art keywords
- thymosin alpha
- treatment
- disease
- ibd
- colitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010078233 Thymalfasin Proteins 0.000 title claims description 30
- 102400000800 Thymosin alpha-1 Human genes 0.000 title claims description 30
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 title claims description 30
- 229960004231 thymalfasin Drugs 0.000 title claims description 30
- 238000011282 treatment Methods 0.000 title claims description 22
- 208000023275 Autoimmune disease Diseases 0.000 title claims description 11
- 239000003814 drug Substances 0.000 title claims description 9
- 230000002265 prevention Effects 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title claims description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 15
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 15
- 208000011231 Crohn disease Diseases 0.000 claims description 14
- 201000006417 multiple sclerosis Diseases 0.000 claims description 11
- 230000002757 inflammatory effect Effects 0.000 claims description 8
- 210000001835 viscera Anatomy 0.000 claims description 3
- 206010009887 colitis Diseases 0.000 description 19
- 230000004054 inflammatory process Effects 0.000 description 15
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 14
- 206010061218 Inflammation Diseases 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 11
- 102100023302 Myelin-oligodendrocyte glycoprotein Human genes 0.000 description 9
- 210000001072 colon Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 7
- 108010083674 Myelin Proteins Proteins 0.000 description 6
- 102000006386 Myelin Proteins Human genes 0.000 description 6
- 102000003896 Myeloperoxidases Human genes 0.000 description 6
- 108090000235 Myeloperoxidases Proteins 0.000 description 6
- 208000025865 Ulcer Diseases 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 210000005012 myelin Anatomy 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 5
- 108010046075 Thymosin Proteins 0.000 description 5
- 102000007501 Thymosin Human genes 0.000 description 5
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000003289 regulatory T cell Anatomy 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 3
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000001524 infective effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 3
- 239000012285 osmium tetroxide Substances 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 229960005205 prednisolone Drugs 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- YNTLVCDWTWUMDV-UHFFFAOYSA-N 4-(4-aminophenyl)-n,2,3-trimethylaniline Chemical compound CC1=C(C)C(NC)=CC=C1C1=CC=C(N)C=C1 YNTLVCDWTWUMDV-UHFFFAOYSA-N 0.000 description 2
- 208000016192 Demyelinating disease Diseases 0.000 description 2
- 206010012305 Demyelination Diseases 0.000 description 2
- 206010016717 Fistula Diseases 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 101800001530 Thymosin alpha Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- MJHYBJOMJPGNMM-KGWLDMEJSA-N [2-[(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 4-(nitrooxymethyl)benzoate Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)C1=CC=C(CO[N+]([O-])=O)C=C1 MJHYBJOMJPGNMM-KGWLDMEJSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 230000003890 fistula Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000003007 myelin sheath Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000000724 thymus hormone Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 208000004881 Amebiasis Diseases 0.000 description 1
- 206010001980 Amoebiasis Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000030767 Autoimmune encephalitis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 101100180402 Caenorhabditis elegans jun-1 gene Proteins 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010061041 Chlamydial infection Diseases 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- 238000012307 MRI technique Methods 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010071141 Rasmussen encephalitis Diseases 0.000 description 1
- 208000004160 Rasmussen subacute encephalitis Diseases 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 206010049416 Short-bowel syndrome Diseases 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000007844 axonal damage Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 201000000902 chlamydia Diseases 0.000 description 1
- 208000012538 chlamydia trachomatis infectious disease Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000008938 immune dysregulation Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 230000002134 immunopathologic effect Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 230000031261 interleukin-10 production Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000005004 lymphoid follicle Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000002314 neuroinflammatory effect Effects 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 230000004776 neurological deficiency Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- 230000004693 neuron damage Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960003753 nitric oxide Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 150000003116 prednisolone derivatives Chemical class 0.000 description 1
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 208000012271 tenesmus Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITRM2006A000584 | 2006-10-27 | ||
| IT000584A ITRM20060584A1 (it) | 2006-10-27 | 2006-10-27 | Uso della timosina alfa 1 la preparazione di un medicamento per la prevenzione e la cura delle malattie autoimmuni |
| PCT/IT2007/000677 WO2008050363A2 (en) | 2006-10-27 | 2007-09-27 | Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of autoimmune diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2007310416A1 true AU2007310416A1 (en) | 2008-05-02 |
Family
ID=39322489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2007310416A Abandoned AU2007310416A1 (en) | 2006-10-27 | 2007-09-27 | Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of autoimmune diseases |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100004174A1 (enExample) |
| EP (1) | EP2086569A2 (enExample) |
| JP (1) | JP2010507650A (enExample) |
| KR (1) | KR20090096688A (enExample) |
| CN (1) | CN101534853A (enExample) |
| AU (1) | AU2007310416A1 (enExample) |
| BR (1) | BRPI0718010A2 (enExample) |
| CA (1) | CA2666609A1 (enExample) |
| EA (1) | EA200900602A1 (enExample) |
| IL (1) | IL198291A0 (enExample) |
| IT (1) | ITRM20060584A1 (enExample) |
| MX (1) | MX2009004196A (enExample) |
| WO (1) | WO2008050363A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100248272A1 (en) * | 2009-03-31 | 2010-09-30 | Cornell University | Method for identifying Smk box riboswitch modulating compounds |
| WO2025078961A1 (en) * | 2023-10-13 | 2025-04-17 | Gufic Biosciences Limited | Composition and method for treatment of endometriosis |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5852225A (ja) * | 1981-09-22 | 1983-03-28 | Mitsui Pharmaceut Inc | 脱髄疾患治療剤 |
| US4444757A (en) * | 1981-11-16 | 1984-04-24 | Research Corporation | Use of thymosin as an anti-diabetes and anti-hypertensive disease agent |
| TW249754B (enExample) * | 1993-10-26 | 1995-06-21 | Alpha I Biomedicals Inc | |
| US5888980A (en) * | 1994-06-30 | 1999-03-30 | Bio-Logic Research And Development Corporation | Compositions for enhancing immune function |
| CA2270223A1 (en) * | 1996-10-28 | 1998-05-07 | Carson B. Burgstiner (Deceased) | Methods and compositions for dietary supplementation |
| CN1198950A (zh) * | 1998-04-24 | 1998-11-18 | 崔泊 | 一种结肠炎新药的制备 |
| CN1628796A (zh) * | 2004-08-20 | 2005-06-22 | 康合堂 | 一种治疗溃疡性结肠炎的药物 |
-
2006
- 2006-10-27 IT IT000584A patent/ITRM20060584A1/it unknown
-
2007
- 2007-09-27 JP JP2009534061A patent/JP2010507650A/ja active Pending
- 2007-09-27 BR BRPI0718010-1A patent/BRPI0718010A2/pt not_active IP Right Cessation
- 2007-09-27 CN CNA200780040140XA patent/CN101534853A/zh active Pending
- 2007-09-27 WO PCT/IT2007/000677 patent/WO2008050363A2/en not_active Ceased
- 2007-09-27 MX MX2009004196A patent/MX2009004196A/es not_active Application Discontinuation
- 2007-09-27 AU AU2007310416A patent/AU2007310416A1/en not_active Abandoned
- 2007-09-27 EA EA200900602A patent/EA200900602A1/ru unknown
- 2007-09-27 EP EP07827728A patent/EP2086569A2/en not_active Withdrawn
- 2007-09-27 CA CA002666609A patent/CA2666609A1/en not_active Abandoned
- 2007-09-27 KR KR1020097007708A patent/KR20090096688A/ko not_active Withdrawn
- 2007-09-27 US US12/446,670 patent/US20100004174A1/en not_active Abandoned
-
2009
- 2009-04-22 IL IL198291A patent/IL198291A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008050363A8 (en) | 2009-06-04 |
| WO2008050363A2 (en) | 2008-05-02 |
| MX2009004196A (es) | 2009-06-30 |
| WO2008050363A3 (en) | 2008-06-26 |
| CA2666609A1 (en) | 2008-05-02 |
| CN101534853A (zh) | 2009-09-16 |
| JP2010507650A (ja) | 2010-03-11 |
| EA200900602A1 (ru) | 2009-10-30 |
| IL198291A0 (en) | 2011-08-01 |
| BRPI0718010A2 (pt) | 2013-11-19 |
| EP2086569A2 (en) | 2009-08-12 |
| US20100004174A1 (en) | 2010-01-07 |
| KR20090096688A (ko) | 2009-09-14 |
| ITRM20060584A1 (it) | 2008-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ridge et al. | Suppression of experimental allergic encephalomyelitis by mitoxantrone | |
| CN111542335A (zh) | 炎症性肠病的治疗药 | |
| US8771689B2 (en) | Alpha B-crystallin as a therapy for ischemia or inflammation | |
| KR20130036217A (ko) | 라퀴니모드를 이용한 루푸스 관절염의 치료 | |
| JP2001511121A (ja) | コポリマー１の摂取又は吸入を通じての多発性硬化症の治療 | |
| Kumar et al. | Novel formulation approaches used for the management of osteoarthritis: A recent review | |
| Jin et al. | The protective effects of nesfatin‐1 in neurological dysfunction after spinal cord injury by inhibiting neuroinflammation | |
| US20100004174A1 (en) | Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of autoimmune diseases | |
| Zhang et al. | Glatiramer acetate ameliorates experimental autoimmune neuritis | |
| JP2009533421A (ja) | 炎症性疾患を治療するためのアセチルコリンエステラーゼに対するアンチセンスオリゴヌクレオチド | |
| CN118178591A (zh) | 一种防治膝骨关节炎的中药组合物及其应用 | |
| JP5536037B2 (ja) | 自己免疫疾患の治療における、ｐａｔノナペプチドの使用 | |
| KR20080048542A (ko) | 인간 유두종 바이러스에 저항하는 약제 제조를 위한노카르디아 루브라 세포벽 골격의 용도 | |
| CN108210886A (zh) | Metrnl在防治溃疡性结肠炎中的应用 | |
| CN116019813A (zh) | Vesatolimod在制备预防和/或治疗中枢神经系统疾病的药物中的应用 | |
| EA032432B1 (ru) | Специфический аналог трифторэтилхинолина для применения при лечении синдрома шегрена | |
| HK1137651A (en) | Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of autoimmune diseases | |
| Yoo et al. | 10-or 30-minute treadmill exercise rescues motor behaviors through inhibiting apoptosis in a rat MCAo model | |
| WO2021240204A1 (en) | Sperm head for resolution of inflammation, tissue repair & regeneration, and restoration of tissue function: new approach of cell therapy | |
| Pan et al. | Angelicin alleviates sepsis-associated encephalopathy via inhibition of IKK2 and the NF-κB pathway | |
| JP2004525978A (ja) | リウマチ関節炎治療用プロディギオシン組成物 | |
| EP4429647A1 (en) | Compositions for the management of demyelinating disorders | |
| CN120983423A (zh) | 狭叶依瓦菊素在制备预防和/或治疗神经炎症的药物中的用途 | |
| Venkataramanaa et al. | Mesenchymal stem cells in spinal cord injury | |
| CN111588854A (zh) | Trf2或其上调剂在制备治疗肌肉疾病的药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |